Tag: Acasti

Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the closing of its previously announced underwritten public offering […]

Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

MONTRÉAL, Oct. 03, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today that it intends to offer and sell its common […]

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

LAVAL, Québec, Oct. 01, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. In accordance with the terms of its outstanding convertible […]

Acasti Pharma Provides Clinical and Market Update

LAVAL, Quebec, Sept. 18, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a clinical and market update. Jan D’Alvise, president […]

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

MONTRÉAL, Aug. 29, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. (“Acasti” […]

Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office

LAVAL, Québec, July 24, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced it has received a Notice of Allowance […]

Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

LAVAL, Québec, June 06, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to […]